Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus.

Nyholm B, Møller N, Gravholt CH, Orskov L, Mengel A, Bryan G, Moyses C, Alberti KG, Schmitz O

The Journal of clinical endocrinology and metabolism1 Mar 1996Cited by 28 (Europe PMC)

PMID8772580DOI10.1210/jcem.81.3.8772580PepBankPUB-08772580

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialMechanism
In patients with IDDM, AC137 did not change glucose disposal during either euglycemic clamp step versus placebo.
In plain wordsIn patients with IDDM, AC137 did not change glucose disposal during normal-glucose clamps compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeEuglycemic glucose disposal
Study
n = 7
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/h in one patient; 50 micrograms/h in six patients · infusion · 330 minAs given in this study (human).
Measurements
Glucose disposal
2.43 mg/kg.min
AC137, euglycemic step 1
Glucose disposal
2.03 mg/kg.min
placebo, euglycemic step 1
Glucose disposal
4.28 mg/kg.min
AC137, euglycemic step 2
Glucose disposal
4.11 mg/kg.min
placebo, euglycemic step 2
Source sentences
Summary
During euglycemia, no differences were found in glucose disposal (step 1, 2.43 +/- 0.20 vs. 2.03 +/- 0.26; step 2, 4.28 +/- 0.54 vs. 4.11 +/- 0.45 mg/kg.min; AC137 vs. placebo, mean +/- SEM), arteriovenous substrate balances across the forearm, or hepatic glucose production.
1 context sentence(design, population, supporting numbers)
Summary · context
To test the acute effect of a human amylin analog (AC137) on glucose metabolism in man, seven IDDM patients were infused in a randomized, double blind, cross-over study with AC137 (100 micrograms/h, n = 1; 50 micrograms/h, n = 6) or placebo for 330 min
Report a problemFND-0877258001
02HumanRandomized controlled trialMechanism
In patients with IDDM, AC137 did not change forearm substrate balances during euglycemia versus placebo.
In plain wordsIn patients with IDDM, AC137 did not change forearm substrate balances during normal glucose conditions compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeForearm arteriovenous substrate balances
Study
n = 7
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/h in one patient; 50 micrograms/h in six patients · infusion · 330 minAs given in this study (human).
Source sentences
Summary
During euglycemia, no differences were found in glucose disposal (step 1, 2.43 +/- 0.20 vs. 2.03 +/- 0.26; step 2, 4.28 +/- 0.54 vs. 4.11 +/- 0.45 mg/kg.min; AC137 vs. placebo, mean +/- SEM), arteriovenous substrate balances across the forearm, or hepatic glucose production.
1 context sentence(design, population, supporting numbers)
Summary · context
To test the acute effect of a human amylin analog (AC137) on glucose metabolism in man, seven IDDM patients were infused in a randomized, double blind, cross-over study with AC137 (100 micrograms/h, n = 1; 50 micrograms/h, n = 6) or placebo for 330 min
Report a problemFND-0877258002
03HumanRandomized controlled trialMechanism
In patients with IDDM, AC137 did not change hepatic glucose production during euglycemia versus placebo.
In plain wordsIn patients with IDDM, AC137 did not change liver glucose production during normal glucose conditions compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeHepatic glucose production
Study
n = 7
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/h in one patient; 50 micrograms/h in six patients · infusion · 330 minAs given in this study (human).
Source sentences
Summary
During euglycemia, no differences were found in glucose disposal (step 1, 2.43 +/- 0.20 vs. 2.03 +/- 0.26; step 2, 4.28 +/- 0.54 vs. 4.11 +/- 0.45 mg/kg.min; AC137 vs. placebo, mean +/- SEM), arteriovenous substrate balances across the forearm, or hepatic glucose production.
1 context sentence(design, population, supporting numbers)
Summary · context
To test the acute effect of a human amylin analog (AC137) on glucose metabolism in man, seven IDDM patients were infused in a randomized, double blind, cross-over study with AC137 (100 micrograms/h, n = 1; 50 micrograms/h, n = 6) or placebo for 330 min
Report a problemFND-0877258003
04HumanRandomized controlled trialMechanism
In patients with IDDM, glucose fluxes during hypoglycemia were similar with AC137 and placebo.
In plain wordsIn patients with IDDM, glucose fluxes during low blood sugar were similar with AC137 and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeHypoglycemic glucose fluxes
Study
n = 7
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/h in one patient; 50 micrograms/h in six patients · infusion · 330 minAs given in this study (human).
Source sentences
Summary
During hypoglycemia, glucose fluxes were also similar.
1 context sentence(design, population, supporting numbers)
Summary · context
To test the acute effect of a human amylin analog (AC137) on glucose metabolism in man, seven IDDM patients were infused in a randomized, double blind, cross-over study with AC137 (100 micrograms/h, n = 1; 50 micrograms/h, n = 6) or placebo for 330 min
Report a problemFND-0877258004
05HumanRandomized controlled trialMechanism
In patients with IDDM, AC137 increased forearm lactate release during hypoglycemia versus placebo.
In plain wordsIn patients with IDDM, AC137 increased forearm lactate release during low blood sugar compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseForearm lactate release
Study
n = 7
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/h in one patient; 50 micrograms/h in six patients · infusion · 330 minAs given in this study (human).
Measurements
Forearm lactate release AUC
−11.2 mmol/min.L
AC137, hypoglycemic clamp
Forearm lactate release AUC
−1.4 mmol/min.L
placebo, hypoglycemic clamp
Source sentences
Summary
However, lactate release from the forearm was more pronounced (P < 0.05) with the analog than with placebo (area under the curve, -11.2 +/- 4.6 vs. -1.4 +/- 2.2 mmol/min.L).
1 context sentence(design, population, supporting numbers)
Summary · context
To test the acute effect of a human amylin analog (AC137) on glucose metabolism in man, seven IDDM patients were infused in a randomized, double blind, cross-over study with AC137 (100 micrograms/h, n = 1; 50 micrograms/h, n = 6) or placebo for 330 min
Report a problemFND-0877258005
06HumanRandomized controlled trialMechanism
In patients with IDDM, plasma glucose nadirs were similar with AC137 and placebo during hypoglycemia.
In plain wordsIn patients with IDDM, the lowest glucose levels were similar with AC137 and placebo during low blood sugar.
Peptide
Pramlintide (Symlin)
Outcome
No significant changePlasma glucose nadir
Study
n = 7
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/h in one patient; 50 micrograms/h in six patients · infusion · 330 minAs given in this study (human).
Measurements
Plasma glucose nadir
2.7 mmol/L
AC137, hypoglycemic clamp
Plasma glucose nadir
2.6 mmol/L
placebo, hypoglycemic clamp
Source sentences
Summary
Despite similar plasma glucose nadirs (2.7 +/- 0.0 vs. 2.6 +/- 0.1 mmol/L; AC137 vs. placebo), circulating cortisol and GH rose to significantly higher levels during hypoglycemia with the amylin analog (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To test the acute effect of a human amylin analog (AC137) on glucose metabolism in man, seven IDDM patients were infused in a randomized, double blind, cross-over study with AC137 (100 micrograms/h, n = 1; 50 micrograms/h, n = 6) or placebo for 330 min
Report a problemFND-0877258006
07HumanRandomized controlled trialMechanism
In patients with IDDM, AC137 increased the cortisol response during hypoglycemia versus placebo.
In plain wordsIn patients with IDDM, AC137 increased cortisol during low blood sugar compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseCortisol response to hypoglycemia
Study
n = 7
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
100 micrograms/h in one patient; 50 micrograms/h in six patients · infusion · 330 minAs given in this study (human).
Source sentences
Summary
Despite similar plasma glucose nadirs (2.7 +/- 0.0 vs. 2.6 +/- 0.1 mmol/L; AC137 vs. placebo), circulating cortisol and GH rose to significantly higher levels during hypoglycemia with the amylin analog (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To test the acute effect of a human amylin analog (AC137) on glucose metabolism in man, seven IDDM patients were infused in a randomized, double blind, cross-over study with AC137 (100 micrograms/h, n = 1; 50 micrograms/h, n = 6) or placebo for 330 min
Report a problemFND-0877258007
08HumanRandomized controlled trialMechanism
In patients with IDDM, AC137 increased the growth hormone response during hypoglycemia versus placebo.
In plain wordsIn patients with IDDM, AC137 increased growth hormone during low blood sugar compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseGrowth hormone response to hypoglycemia
Study
n = 7
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms/h in one patient; 50 micrograms/h in six patients · infusion · 330 minAs given in this study (human).
Source sentences
Summary
Despite similar plasma glucose nadirs (2.7 +/- 0.0 vs. 2.6 +/- 0.1 mmol/L; AC137 vs. placebo), circulating cortisol and GH rose to significantly higher levels during hypoglycemia with the amylin analog (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To test the acute effect of a human amylin analog (AC137) on glucose metabolism in man, seven IDDM patients were infused in a randomized, double blind, cross-over study with AC137 (100 micrograms/h, n = 1; 50 micrograms/h, n = 6) or placebo for 330 min
Report a problemFND-0877258008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.